Related Experiment Video
Updated: Aug 16, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
[Sumatriptan--future development, alternative features and potential new indications]
1International Medical Affairs Division, Glaxo Group Research, Greenford, UK.
Neurologia I Neurochirurgia Polska
|January 1, 1992
Summary
Sumatriptan effectively treats acute migraine and cluster headaches. New formulations and routes of administration are being developed to improve patient access and address gastrointestinal issues.
Area of Science:
- Pharmacology
- Neurology
Context:
- Sumatriptan is a selective 5 HT1 receptor agonist used for acute migraine treatment.
- Migraine and cluster headache patients often experience gastrointestinal symptoms, complicating oral medication.
- Alternative sumatriptan delivery methods are needed for patients who cannot use oral or subcutaneous forms.
Purpose:
- To review the efficacy and safety of sumatriptan in acute treatment of migraine and cluster headaches.
- To explore alternative sumatriptan formulations and routes of administration for improved patient compliance and effectiveness.
- To investigate new indications for sumatriptan, including menstrual migraine and pediatric migraine.
Summary:
- Sumatriptan tablets and injections are effective and well-tolerated for acute migraine.
- Gastrointestinal symptoms in migraineurs can make oral sumatriptan unsatisfactory.
- Subcutaneous sumatriptan is effective but not suitable for all patients.
- Intranasal, rectal, and effervescent tablet formulations are under investigation.
- Sumatriptan has shown efficacy in treating cluster headaches.
- New indications, including menstrual and pediatric migraine, are being explored.
Impact:
- Sumatriptan provides effective relief for migraine and cluster headaches.
- Development of alternative sumatriptan formulations aims to improve treatment accessibility and patient outcomes.
- Expanding sumatriptan's indications may benefit a wider range of headache sufferers.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...